Sanofi launches multiple sclerosis treatment drug in India

07 Aug 2018 Evaluate

Sanofi’s specialty care global business unit -- Sanofi Genzyme has launched its multiple sclerosis treatment drug ‘Aubagio’ in India. The drug offers patients diagnosed with multiple sclerosis the efficacy and convenience of once-a-day oral treatment.

Aubagio is a differentiated disease modifying therapy that blocks the enzyme involved in multiplication of overactive immune cells.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

4334.40 -37.30 (-0.85%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×